Urinary Bladder, Overactive: all 864 studies

Page 3 of 9. Open to participants first (125), then studies with results posted, then the rest; newest registration first within each.

• Foot/Hand Neuromodulation for Overactive Bladder (OAB)TerminatedNCT01972061Not applicableResults posted
• OnabotulinumtoxinA (BOTOX®) Treatment for Urinary Incontinence in Patients With Overactive BladderCompletedNCT01945489Phase 4Results posted
• Drug Use Investigation for ToviazCompletedNCT01936870Results posted
• The Effect of Anticholinergics on Cognitive Function in the ElderlyCompletedNCT01922115Phase 4Results posted
• A Trial Comparing Combination Treatment (Solifenacin Plus Mirabegron) With One Treatment Alone (Solifenacin)CompletedNCT01908829Phase 3Results posted
• Utilization of the BIOWAVE Device to Treat Overactive BladderCompletedNCT01848366Not applicableResults posted
• Plantarflexion Reduces Urgency and Peak Detrusor Pressure in Patients With Detrusor OveractivityCompletedNCT01837654Not applicableResults posted
• Extended-Release Oxybutynin for the Treatment of Neurogenic Detrusor OveractivityTerminatedNCT01796548Phase 4Results posted
• VESIcare For Improving OAB Symptoms in Patients Undergoing IGRT of the ProstateTerminatedNCT01777217Phase 4Results posted
• A Study Evaluating the Efficacy and Safety of BOTOX® or Solifenacin in Patients With Overactive Bladder and Urinary IncontinenceCompletedNCT01767519Phase 3Results posted
• A Study to Evaluate the Effect of Mirabegron + Solifenacin in Overactive Bladder PatientsCompletedNCT01745094Phase 4Results posted
• A Single-Dose Study of the Pharmacokinetics of Vibegron (MK-4618) in Adults With Hepatic Insufficiency (MK-4618-013)CompletedNCT01737684Phase 1Results posted
• Interventional Clinical Trial in Patients in Overactive Bladder With Nocturia in WomenCompletedNCT01729819Phase 2Results posted
• A Study to Investigate How Safe and Effective Solifenacin Solution is in Treating Children/Adolescents With Symptoms of Overactive Bladder (OAB) Who Completed Study 905-CL-076CompletedNCT01655069Phase 3Results posted
• Bacterial Genomic Sequencing in Overactive BladderCompletedNCT01642277Phase 2Results posted
• A Study to Evaluate the Efficacy and Safety of Mirabegron Compared to Solifenacin in Patients With Overactive Bladder Who Were Previously Treated With Another Medicine But Were Not Satisfied With That Treatment.CompletedNCT01638000Phase 3Results posted
• A Single Dose Study of the Pharmacokinetics of Vibegron (MK-4618) in Participants With Renal Insufficiency (MK-4618-014)CompletedNCT01628042Phase 1Results posted
• Trial of Percutaneous Tibial Nerve Stimulation (PTNS) Versus PTNS and Fesoterodine FumarateTerminatedNCT01605617Phase 4Results posted
• A Study to Investigate How Effective and Safe Solifenacin Succinate Suspension is in Treating Children/Adolescents Aged 5 to Less Than 18 Years With Symptoms of Overactive Bladder (OAB) Compared to a Non-active DrugCompletedNCT01565707Phase 3Results posted
• A Study to Assess the Long Term Effect, Safety and Metabolism of a Solifenacin Liquid Suspension in Participants 5 to 18 Years of Age With Neurogenic Detrusor OveractivityCompletedNCT01565694Phase 3Results posted
• The Efficacy of Solifenacin With or Without Tamsulosin in Adult Women With Overactive Bladder (OAB)CompletedNCT01533597Phase 4Results posted
• Refractory Overactive Bladder: Sacral NEuromodulation v. BoTulinum Toxin Assessment (ROSETTA)CompletedNCT01502956Phase 3Results posted
• A Study of the Pharmacokinetics and Pharmacodynamics of Vibegron (MK-4618) in Women With Overactive Bladder (MK-4618-004)TerminatedNCT01500382Phase 1Results posted
• Tolterodine Drug Use Investigation.(Post Marketing Commitment Plan)CompletedNCT01488578Results posted
• Therapeutic Merit of Solifenacin in the Mitigation of Ureteral Stent-induced Pain and Lower Urinary Tract SymptomsCompletedNCT01381120Phase 4Results posted
• Safety and Effectiveness of a Non-invasive Neuromodulation Device on Urgency Urinary Incontinence in Overactive BladderCompletedNCT01369485Not applicableResults posted
• Comparative Urine Proteomic Studies of Overactive Bladder in HumansCompletedNCT01367886Not applicableResults posted
• A Study to Evaluate the Efficacy, Safety and Tolerability of Mirabegron and Solifenacin Succinate Alone and in Combination for the Treatment of Overactive BladderCompletedNCT01340027Phase 2Results posted
• A Study of the Efficacy and Safety of Vibegron (MK-4618) in Participants With Overactive Bladder (OAB) (MK-4618-008)CompletedNCT01314872Phase 2Results posted
• Web-based Methodology Trial to Evaluate the Efficacy and Safety of Tolterodine ER in Subjects With Overactive BladderTerminatedNCT01302938Phase 4Results posted
• A 12 Week Study to Confirm the Effectiveness of 8mg of Fesoterodine Compared to 4mg of FesoterodineCompletedNCT01302067Phase 4Results posted
• A Clinical Study in Patients With Overactive Bladder With Leakage of Urine, to Find Out if the Medicine, Fesoterodine, Works in Those Patients Who Did Not Have Enough Response to the Medicine, Tolterodine.CompletedNCT01302054Phase 4Results posted
• This Is A Study Of Bioavailability And Food Effect For Fesoterodine.CompletedNCT01286454Phase 1Results posted
• Post Marketing Surveillance Of Fesoterodine In Filipino Patients With Over Active BladderCompletedNCT01260311Results posted
• Botox for the Treatment of Overactive Bladder Secondary to Benign Prostatic ObstructionCompletedNCT01220726Phase 3Results posted
• Evaluating the Change of Overactive Bladder Symptoms in Women Post Pubovaginal Sling Procedure for Stress IncontinenceCompletedNCT01194999Phase 4Results posted
• Safety and Efficacy Evaluation of Oxybutynin Topical Gel In Children With Neurogenic BladderCompletedNCT01192568Phase 4Results posted
• Preoperative Use of Darifenacin (Enablex) to Alleviate Postoperative Ureteral Stent PainTerminatedNCT01189071Not applicableResults posted
• Behavioral Treatment of Overactive Bladder in MenCompletedNCT01187498Phase 3Results posted
• Sanctura Muscarinic Receptor Antagonist Resists Transport (SMART-II) TrialCompletedNCT01178827Phase 4Results posted
• Combined Behavioral and Drug Treatment of Overactive Bladder in MenCompletedNCT01175382Phase 2/3Results posted
• Effects and Safety of Liposome Encapsulated Botulinum Toxin A for Overactive Bladder SyndromeCompletedNCT01167257Phase 2Results posted
• Anticholinergic vs. Botox Comparison StudyCompletedNCT01166438Phase 3Results posted
• Safety and Efficacy Study of AGN-214868 in Patients With Idiopathic Overactive Bladder and Urinary IncontinenceCompletedNCT01157377Phase 2Results posted
• Clinical Trial to Study a Non-invasive Neurostimulation Device on Urgency (Urinary) Incontinence Overactive Bladder (OAB)CompletedNCT01125722Not applicableResults posted
• Study of 2 Doses of Solifenacin Succinate in Female Subjects With Overactive Bladder.CompletedNCT01093534Phase 4Results posted
• Non-Interventional Study To Investigate Whether Information Provided To Patients Influences Their Satisfaction With Toviaz TherapyTerminatedNCT01091519Results posted
• Efficacy of Sanctura XR (Trospium Chloride) for Reducing Overactive Bladder Symptoms in Female Subjects Refractory to Detrol LA (Tolterodine Tartrate Extended Release) DailyCompletedNCT01089751Phase 4Results posted
• Local, Open-Label, Extension Trial Of The Efficacy And Safety Of Fesoterodine In Elderly Patients With Overactive BladderCompletedNCT01054222Phase 4Results posted
• Efficacy Study of Pudendal Neuromodulation for the Treatment of Neurogenic Overactive BladderTerminatedNCT01023269Not applicableResults posted
• Solifenacin Succinate (VESIcare) for the Treatment of Overactive Bladder in Parkinson's DiseaseCompletedNCT01018264Phase 4Results posted
• Dysfunctional Voiding and Lower Urinary Tract Symptoms With BaclofenTerminatedNCT01003249Phase 4Results posted
• Comparison of Motor and Sensory Response With Interstim StimulationCompletedNCT00943904Not applicableResults posted
• This Is An Open-Label Study To Evaluate Fesoterodine Plus "Your Way" Patient Support Plan In Patients With Symptoms Of Overactive BladderCompletedNCT00943735Results posted
• Trospium Chloride XR in Obese Female Patients With Overactive BladderCompletedNCT00932022Phase 4Results posted
• Modified Extension Study to the SUmiT Trial: Evaluation of Long Term Therapy With Percutaneous Tibial Nerve Stimulation (PTNS) for Overactive Bladder SymptomsCompletedNCT00928395Phase 4Results posted
• A Study Of Efficacy And Safety Of Fesoterodine In Vulnerable Elderly Subjects With Overactive BladderCompletedNCT00928070Phase 4Results posted
• Long Term Follow-up Study of Safety and Efficacy of Botulinum Toxin Type A for the Treatment of Patients With Idiopathic Overactive Bladder With Urinary IncontinenceCompletedNCT00915525Phase 3Results posted
• A Study to Test the Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive BladderCompletedNCT00912964Phase 3Results posted
• A Trial To Evaluate The Efficacy And Safety Of Fesoterodine In Patients With Symptoms Of Overactive Bladder Including Nocturnal Urinary UrgencyCompletedNCT00911937Phase 4Results posted
• Study of Botulinum Toxin Type A for the Treatment of Patients With Idiopathic Overactive Bladder With Urinary IncontinenceCompletedNCT00910845Phase 3Results posted
• Botulinum Toxin Type A for the Treatment of Patients With Idiopathic Overactive Bladder With Urinary IncontinenceCompletedNCT00910520Phase 3Results posted
• Validation of a Real-time Urodynamic Measure of Urinary UrgencyCompletedNCT00909428Phase 4Results posted
• Toviaz Post Marketing Surveillance StudyCompletedNCT00879398Results posted
• A Long-term Follow-up Study of Botulinum Toxin Type A in Patients With Overactive Bladder as a Result of Spinal Injury or Multiple SclerosisCompletedNCT00876447Phase 3Results posted
• Tetra-NIRS Clinical StudyTerminatedNCT00871975Phase 4Results posted
• Urinary Cytokines in Patients With Overactive Bladder (OAB)CompletedNCT00868621Results posted
• Sanctura Muscarinic Receptor Antagonist Resists Transport (SMART) TrialCompletedNCT00863551Phase 4Results posted
• Bringing Simple Urge Incontinence Diagnosis & Treatment to Providers (BRIDGES)CompletedNCT00862745Phase 4Results posted
• Study Of Fesoterodine In Pediatric Overactive Bladder Patients Aged 8-17 YearsCompletedNCT00857896Phase 2Results posted
• Over Active Bladder Patients Having Sling SurgeryTerminatedNCT00852696Not applicableResults posted
• Behavioral Modification and Vesicare Versus Vesicare Alone for Urge Incontinence in Patients With Overactive BladderTerminatedNCT00821184Phase 3Results posted
• UK Study Assessing Flexible Dose Fesoterodine in AdultsCompletedNCT00806494Phase 4Results posted
• A Study to Compare the Effectiveness and Safety of Fesoterodine and Placebo in an Elderly Population of Patients Who go to the Toilet Very Frequently Due to Overactive Bladder.CompletedNCT00798434Phase 4Results posted
• Special Investigation For Long Term Use Of Tolterodine (Regulatory Post Marketing Commitment Plan).CompletedNCT00795509Results posted
• Hypnotherapy for Treatment of Overactive BladderCompletedNCT00793611Not applicableResults posted
• Study of Urgent PC Versus Sham Effectiveness in Treatment of Overactive Bladder SymptomsCompletedNCT00771264Phase 4Results posted
• A Study to Test the Effects of Tolterodine Tartrate in Patients With Overactive Bladder (0000-107)CompletedNCT00768521Phase 1Results posted
• Feasibility of "At-home" Titration of SolifenacinTerminatedNCT00759577Phase 4Results posted
• Pilot Study: Is Overactive Bladder Caused by Subacute Urinary Tract Infections?CompletedNCT00714792Results posted
• A Two-week Open-label Pharmacodynamic and Pharmacokinetic Study of Multiple Doses of a Darifenacin Liquid Oral Suspension in Children (2 - 15 Years) With Neurogenic Detrusor OveractivityTerminatedNCT00712322Phase 2Results posted
• Uro-NIRS Clinical StudyCompletedNCT00706407Not applicableResults posted
• Study In Patients With Overactive Bladder Treated With Toviaz® After Failure Of Previous TherapyCompletedNCT00691093Results posted
• Study to Assess the Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive BladderCompletedNCT00689104Phase 3Results posted
• Study to Test the Long Term Safety and Efficacy of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive BladderCompletedNCT00688688Phase 3Results posted
• A Parallel Group Study to Compare Sativex® With Placebo in the Treatment of Detrusor Overactivity in Patients With Multiple SclerosisCompletedNCT00678795Phase 3Results posted
• Over Active Bladder Instillation Study - BotoxTerminatedNCT00667095Phase 3Results posted
• A Study to Assess Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive BladderCompletedNCT00662909Phase 3Results posted
• Long Term Study To Evaluate the Safety, Tolerability and Efficacy of Fesoterodine for Overactive Bladder.CompletedNCT00658684Phase 3Results posted
• An Efficacy and Safety Study of Oxybutynin Chloride Oral Osmotic Therapeutic System (OROS) in Korean Overactive Bladder ParticipantsCompletedNCT00613327Phase 4Results posted
• Clinical Trial to Evaluate the Efficacy and Safety of Fesoterodine in Comparison to Tolterodine Extended Release(ER)in Patients With Overactive Bladder.CompletedNCT00611026Phase 3Results posted
• Botulin-A Toxin Instillations and Overactive BladderCompletedNCT00583219Phase 1/2Results posted
• Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Neurogenic Overactive BladderTerminatedNCT00575016Phase 2Results posted
• Study of VESIcare® In Overactive Bladder (OAB) Subjects to Evaluate Symptom Bother and Health Related Quality of LifeCompletedNCT00573508Phase 4Results posted
• Dose-Finding Study To Evaluate The Efficacy, Tolerability And Safety Of Fesoterodine In Comparison To Placebo For Overactive Bladder.CompletedNCT00561951Phase 2Results posted
• InSite for Over Active BladderCompletedNCT00547378Phase 4Results posted
• Fesoterodine "add-on" Male Overactive Bladder StudyCompletedNCT00546637Phase 3Results posted
• Fesoterodine Flexible Dose StudyCompletedNCT00536484Phase 3Results posted
• A Study To Assess If 10 mg Vardenafil (BAY38-9456) Taken Twice Daily For 6 Weeks Has An Effect On Bladder FunctionCompletedNCT00478881Phase 2Results posted
• Detrol Long Acting (LA) vs Estrace Vaginal Cream for the Treatment of Overactive Bladder SymptomsCompletedNCT00465894Not applicableResults posted

← Urinary Bladder, Overactive overview